Saturn V Capital Sells $14M in Dyne Therapeutics Shares Despite Stock Rising 40%
Saturn V Capital Management LP sold $14.17 million worth of shares in Dyne Therapeutics during Q1, despite the stock rising nearly 40% over the past year and outperforming broader market indices.
Tickers: $DYN
Topics: biotech SEC filing stock sales